ProCE Banner Activity

CE

Personalized Treatment in Myelofibrosis: Applying the Data to Address Barriers and Improve Care

Video

Watch this on-demand webcast from a live Asembia satellite symposium to learn from clinical and specialty pharmacists about best practices for individualized management of patients with myelofibrosis, including evidence-based treatment options and the role of pharmacists in providing patient support, symptom and toxicity management, and monitoring.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: June 07, 2023

Expiration: June 06, 2024

No longer available for credit.

Share

Faculty

Emily Hollinghurst

Emily Hollinghurst, PharmD, BCOP, CSP, APh

Assistant Professor
Department of Pharmacy Practice
Loma Linda University, School of Pharmacy
Clinical Pharmacy Specialist
Specialty Pharmacy Services
Loma Linda University Medical Center
Loma Linda, California

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GSK.

GSK

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with myelofibrosis as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners about medication therapy management of myelofibrosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss myelofibrosis risk stratification, symptom assessment, and therapy response evaluation

  • Develop evidence-based first- and second-line, risk-informed treatment plans for myelofibrosis that incorporate the latest clinical trial evidence into therapy selection and sequencing

  • Develop strategies to improve patient quality of life by minimizing disease symptoms and treatment-related toxicities

  • Implement a patient management program to ensure appropriate outcomes monitoring for therapy responsiveness and adverse events in patients receiving therapy for myelofibrosis

Disclosure

ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Emily Hollinghurst, PharmD, BCOP, CSP, APh

Assistant Professor
Department of Pharmacy Practice
Loma Linda University, School of Pharmacy
Clinical Pharmacy Specialist
Specialty Pharmacy Services
Loma Linda University Medical Center
Loma Linda, California

Emily Hollinghurst, PharmD, BCOP, CSP, APh: consultant/advisor/speaker: Eisai.

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Victoria Nachar, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-011-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.